COO COOPER COMPANIES, INC.
Ophthalmic Goods · Nasdaq · SEC CIK 711404 · Fiscal year ends 10/31
Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.7%
TTM net income YoY39.8%
TTM EPS YoY42.6%
Revenue 3-yr CAGR6.4%
Net income 3-yr CAGR27.5%
Margins
Gross margin65.9%
Operating margin12.8%
Net margin13.5%
FCF margin16.0%
EBITDA margin19.7%
Returns
ROE6.8%
ROA4.6%
ROIC (approx.)5.1%
Asset turnover0.34x
Leverage & solvency
Liabilities / assets34.3%
Debt / equity0.31x
Current ratio1.22x
Interest coverage6.10x
Cash quality & payout
Operating cash flow / net income1.81x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue8.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-10-31 | FY20242024-10-31 | FY20232023-10-31 | FY20222022-10-31 | FY20212021-10-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.09B | $3.90B | $3.59B | $3.31B | $2.92B |
| Cost of revenue | $1.41B | $1.30B | $1.24B | $1.17B | $966.70M |
| Gross profit | $2.68B | $2.60B | $2.36B | $2.14B | $1.96B |
| R&D expense | $172.20M | $155.10M | $137.40M | $110.30M | $92.70M |
| SG&A expense | $1.63B | $1.53B | $1.50B | $1.34B | $1.21B |
| Operating income | $682.90M | $705.70M | $533.10M | $507.60M | $505.80M |
| Interest expense | $100.00M | $114.30M | $105.30M | $57.30M | $23.10M |
| Pretax income | $566.50M | $582.30M | $412.90M | $475.30M | $491.50M |
| Income tax | $191.60M | $190.00M | $118.70M | $89.50M | -$2.45B |
| Net income | $374.90M | $392.30M | $294.20M | $385.80M | $2.94B |
| EBITDA | $1.06B | $1.08B | $900.80M | $853.70M | $815.10M |
| EPS (basic) | 1.88 | 1.97 | 1.49 | 1.95 | 59.80 |
| EPS (diluted) | 1.87 | 1.96 | 1.48 | 1.94 | 59.16 |
| Dividends declared per share | — | — | 0.01 | 0.01 | 0.03 |
| Weighted avg. shares (diluted) | 200.00M | 200.40M | 199.30M | 198.80M | 49.80M |
| Balance sheet | |||||
| Cash & equivalents | $110.60M | $107.70M | $120.80M | $138.60M | $96.60M |
| Receivables | $829.00M | $717.00M | $609.70M | $557.80M | $515.30M |
| Inventory | $846.00M | $802.70M | $735.60M | $628.70M | $585.60M |
| Current assets | $2.11B | $1.95B | $1.70B | $1.53B | $1.47B |
| PP&E, net | $2.08B | $1.86B | $1.63B | $1.43B | $1.35B |
| Goodwill | $3.85B | $3.84B | $3.62B | $3.61B | $2.57B |
| Intangibles | $1.59B | $1.79B | $1.71B | $1.89B | $1.27B |
| Total assets | $12.39B | $12.32B | $11.66B | $11.49B | $9.61B |
| Current liabilities | $1.11B | $1.02B | $969.00M | $1.28B | $732.10M |
| Short-term debt | $47.80M | $33.30M | $45.40M | $412.60M | $83.40M |
| Long-term debt | $2.46B | $2.55B | $2.52B | $2.35B | $1.40B |
| Total debt | $2.50B | $2.58B | $2.57B | $2.76B | $1.48B |
| Total liabilities | $4.16B | $4.23B | $4.11B | $4.32B | $2.66B |
| Shareholders' equity | $8.24B | $8.08B | $7.55B | $7.17B | $6.94B |
| Net debt | $2.39B | $2.47B | $2.44B | $2.62B | $1.38B |
| Shares outstanding | 195.90M | 199.60M | 198.10M | 49.30M | 49.30M |
| Cash flow statement | |||||
| Operating cash flow | $796.10M | $709.30M | $607.50M | $692.40M | $738.60M |
| Capital expenditure | $362.40M | $421.20M | $392.50M | $242.00M | $214.40M |
| Free cash flow | $433.70M | $288.10M | $215.00M | $450.40M | $524.20M |
| Investing cash flow | -$372.90M | -$764.60M | -$449.00M | -$1.83B | -$450.30M |
| Financing cash flow | -$425.90M | $39.20M | -$173.90M | $1.19B | -$311.40M |
| Depreciation & amortization | $377.40M | $375.10M | $367.70M | $346.10M | $309.30M |
| Stock-based compensation | $70.50M | $75.10M | $62.10M | $54.20M | $43.80M |
| Dividends paid | $0 | $0 | $3.00M | $3.00M | $3.00M |
| Share buybacks | $290.10M | $0 | $0 | $78.50M | $24.80M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.